Revolution Medicines
700 Saginaw Drive
Redwood City
California
94063
United States
97 articles with Revolution Medicines
-
Revolution Medicines Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
3/7/2023
Revolution Medicines, Inc., a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, announced the closing of its underwritten public offering of 15,681,818 shares of common stock at a public offering price of $22.00 per share, before underwriting discounts and commissions.
-
Revolution Medicines Announces Pricing of $300.0 Million Public Offering of Common Stock
3/3/2023
Revolution Medicines, Inc., a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, announced the pricing of its underwritten public offering of 13,636,364 shares of common stock at a public offering price of $22.00 per share, before underwriting discounts and commissions.
-
Revolution Medicines Announces Commencement of Public Offering of Common Stock
3/1/2023
Revolution Medicines, Inc., a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, announced that it has commenced an underwritten public offering to sell up to $300 million of shares of its common stock.
-
Revolution Medicines Reports Fourth Quarter and Full Year 2022 Financial Results and Update on Corporate Progress
2/27/2023
Revolution Medicines, Inc. announced its financial results for the quarter and year ended December 31, 2022, and provided an update on corporate progress.
-
Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2022 After Market Close on February 27, 2023
2/21/2023
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today announced that it will report financial results for the fourth quarter and full year 2022 on Monday, February 27, 2023, after market close.
-
Revolution Medicines to Participate in Upcoming Investor Conferences
2/2/2023
Revolution Medicines, Inc. today announced that the company will participate in two upcoming investor conferences. Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will be the featured speaker in fireside chats at the Guggenheim Healthcare Talks 2023 Oncology Conference.
-
Revolution Medicines to Present at 41st Annual J.P. Morgan Healthcare Conference
1/3/2023
Revolution Medicines, Inc. announced that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will deliver a corporate presentation as part of the 41st Annual J.P. Morgan Healthcare Conference.
-
Revolution Medicines Announces Publication Describing Design and Synthesis of RMC-5552, a First-in-Class, Bi-Steric mTORC1-Selective Inhibitor
12/19/2022
Revolution Medicines, Inc. today announced publication of a manuscript in the Journal of Medicinal Chemistry that details the discovery efforts leading to RMC-5552, the company’s first-in-class, bi-steric mTORC1-selective inhibitor.
-
Sanofi has terminated its global development and commercialization pact with Revolution Medicines, Inc. for their SHP2 inhibitor drug candidate,
-
Revolution Medicines to Regain Global Rights to RMC-4630 following Sanofi’s Termination of SHP2 Inhibitor Development and Commercialization Collaboration
12/7/2022
Revolution Medicines, Inc., a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, announced that Sanofi has provided notice of termination of the parties’ global SHP2 development and commercialization collaboration.
-
Revolution Medicines to Participate in Upcoming Investor Conferences - November 09, 2022
11/9/2022
Revolution Medicines, Inc., a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, announced that the company will participate in two upcoming investor conferences.
-
Revolution Medicines Reports Third Quarter 2022 Financial Results and Update on Corporate Progress
11/7/2022
Revolution Medicines, Inc., a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, announced its financial results for the quarter ended September 30, 2022, and provided an update on corporate progress.
-
Revolution Medicines to Report Financial Results for Third Quarter 2022 After Market Close on November 7, 2022
11/1/2022
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today announced that it will report financial results for the third quarter 2022 on Monday, November 7, 2022, after market close.
-
Revolution Medicines Doses First Patient in Phase 1/1b Clinical Trial of RMC-6291, Company’s First Mutant-Selective RAS(ON) Inhibitor
9/22/2022
Revolution Medicines, Inc. today announced the first patient was dosed in its Phase 1/1b monotherapy clinical trial of RMC-6291, an oral, selective, covalent KRASG12C(ON) Inhibitor designed to treat patients with cancers driven by the KRASG12C mutation.
-
Revolution Medicines Strengthens Senior Management Team with Promotions and a New Hire
9/1/2022
Revolution Medicines, Inc., a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, announced two senior management promotions, as well as the addition of a new member to its leadership team.
-
Revolution Medicines to Participate in Upcoming Investor Conferences in September 2022
8/31/2022
Revolution Medicines, Inc., a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, announced that the company will participate in two upcoming investor conferences.
-
Revolution Medicines Reports Second Quarter 2022 Financial Results and Update on Corporate Progress
8/9/2022
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced its financial results for the quarter ended June 30, 2022, and provided an update on corporate progress.
-
Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares - July 22, 2022
7/22/2022
Revolution Medicines, Inc., a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, announced the closing of an underwritten public offering of 13,225,000 shares of common stock at a public offering price of $20.00 per share, before underwriting discounts and commissions.
-
Revolution Medicines Announces Pricing of Upsized $230.0 Million Public Offering of Common Stock
7/20/2022
Revolution Medicines, Inc., a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, announced the pricing of its underwritten public offering of 11,500,000 shares of common stock at a public offering price of $20.00 per share, before underwriting discounts and commissions.
-
Revolution Medicines Announces Commencement of Public Offering of Common Stock - July 19, 2022
7/19/2022
Revolution Medicines, Inc., a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, announced that it has commenced an underwritten public offering to sell up to $200 million of shares of its common stock.